SCHEMBL22632566

SCHEMBL22632566

CCCCCc1n[nH]c2ccc(Br)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 3/20 0.50
JAK2 O60674 2/20 0.50
FLT3 P36888 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
DYRK1A Q13627 2/20 0.45
DCLK1 O15075 1/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
CHEK2 O96017 1/20 0.45
CSF1R P07333 1/20 0.45
FER P16591 1/20 0.45
CDK2 P24941 1/20 0.45
MARK3 P27448 1/20 0.45
FLT4 P35916 1/20 0.45
MAPK9 P45984 1/20 0.45
CSNK1D P48730 1/20 0.45
CLK2 P49760 1/20 0.45
CSNK2A1 P68400 1/20 0.45
CSNK1G2 P78368 1/20 0.45
MAP4K2 Q12851 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144803 0.89 PDPK1 (0.54) PDPK1JAK2FLT3CLK4DYRK1A
SCHEMBL8138818 0.83 PDPK1 (0.56) PDPK1JAK2FLT3CLK4DYRK1A
SCHEMBL15826217 0.83 HTR1A (0.48) GSK3BHTR2AHTR2CSLC6A4HTR1A
SCHEMBL1049315 0.82 PDPK1 (0.47) PDPK1JAK2FLT3CLK4DYRK1A
SCHEMBL182234 0.82 PDPK1 (0.58) PDPK1JAK2FLT3CLK4DYRK1A
SCHEMBL7134511 0.82 CYP3A4 (0.44) HTR2AHTR2CHTR2BSLC6A4HTR1A
SCHEMBL24025971 0.79 HTR1A (0.38) CDK2GSK3BHTR2AHTR2CHTR2B
SCHEMBL22643956 0.79 HTR1D (0.40) GSK3B
SCHEMBL14863730 0.78 MEN1 (0.47) SLC6A4HTR1ACHUK
SCHEMBL7740374 0.78 MAPT (0.50) FADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036699-A THR-beta modulators and methods of use thereof 阿利戈斯治疗公司 2026-05-15 CN disclosed
US-20250304561-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2025-10-02 US disclosed
EP-4523692-A2 MODULATORS OF THR-SS AND METHODS OF USE THEREOF Aligos Therapeutics, Inc. (US) 2025-03-19 EP disclosed
EP-3965884-B1 MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP ALIGOS THERAPEUTICS INC (US) 2025-01-15 EP disclosed
US-12180192-B2 Modulators of THR-β and methods of use thereof ALIGOS THERAPEUTICS, INC. (US) 2024-12-31 US disclosed
EP-3965884-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF Aligos Therapeutics, Inc. (US) 2022-03-16 EP disclosed
CN-114096531-A THR-beta modulators and methods of use thereof 阿利戈斯治疗公司 2022-02-25 CN disclosed
US-20210355112-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2021-11-18 US disclosed
US-20210355112-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2021-11-18 US disclosed
US-11091467-B2 Modulators of THR-β and methods of use thereof ALIGOS THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-11091467-B2 Modulators of THR-β and methods of use thereof ALIGOS THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-20200354345-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2020-11-12 US disclosed
US-20200354345-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2020-11-12 US disclosed
WO-2020227549-A1 MODULATORS OF THR-β AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355112-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF THRB, THRA, TRHR PDPK1 2836/4885JAK2 273/4885FLT3 705/4885
US-20250304561-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF THRB, THRA, TRHR PDPK1 2757/4885JAK2 238/4885FLT3 308/4885
US-20200354345-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF THRB, THRA, TRHR PDPK1 2836/4885JAK2 273/4885FLT3 705/4885
US-12180192-B2 Modulators of THR-β and methods of use thereof THRB, THRA, TRHR PDPK1 2626/4885JAK2 196/4885FLT3 535/4885
US-11091467-B2 Modulators of THR-β and methods of use thereof THRB, THRA, TRHR PDPK1 2626/4885JAK2 196/4885FLT3 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.